Lamivudine Accord (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics natural nucleosides. When HIV reverse transcriptase incorporates lamivudine triphosphate into viral DNA, the lack of a 3'-hydroxyl group stops further DNA chain elongation, effectively terminating viral replication.

The specific dose of Lamivudine Accord is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. Healthcare professionals set the appropriate regimen according to current treatment guidelines.

Safety of lamivudine during pregnancy or lactation should be evaluated by a qualified healthcare provider. The drug may be prescribed if the potential benefits outweigh any possible risks to the fetus or infant, and decisions are made on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often used in combination regimens. Compared with other NRTIs, it has a favorable safety profile and low pill burden, but resistance can develop if used without adequate companion drugs. Clinicians select it based on efficacy, resistance patterns, and patient tolerance.

Lamivudine Accord should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Lamivudine Accord is taken orally, usually as a tablet, with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional and swallow the tablet whole with water.

The most serious adverse events linked to lamivudine include lactic acidosis, severe hepatotoxicity, pancreatitis, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if patients experience symptoms like unexplained fatigue, abdominal pain, jaundice, or severe skin rash.

Lamivudine should be avoided in individuals with known hypersensitivity to the drug or any of its components. Patients with severe renal impairment may require dose adjustment, and those on contraindicated drug combinations, such as didanosine or stavudine, should not use it without medical supervision.